New FDA Approved Cosmetic Peptide Tirzepatide LY3298176 10mg And 15mg Vials

New FDA Approved Cosmetic Peptide Tirzepatide LY3298176 10mg And 15mg Vials

Product desciption:

Current clinical data has demonstrated that tirzepatide is superior to placebo in improving hemoglobin A1C levels. The SURPASS-5 clinical trial showed a -2.11% reduction in hemoglobin A1C levels at 5mg per week dosing, compared to -0.86% with placebo. At the highest dose of 15 mg per week, tirzepatide led to a -2.34% reduction in hemoglobin A1C. This was demonstrated over 40 weeks. A weight reduction of 5.4 kg was seen with 5mg of tirzepatide dosing, and a 10.5 kg reduction was seen with 15 mg dosing. This dose-dependent correlation with weight loss is similar to semaglutide, a common GLP-1 medication utilized for weight loss management.

Comparatively, tirzepatide has been shown to work similarly to GLP-1 medications but with greater efficacy. Given its weight loss properties and lack of liver toxicity,[4] it is likely to play an indirect role in the treatment of nonalcoholic fatty liver disease (NAFLD) as well; however, further research is needed before it is approved for NAFLD.

Objectives:

• Review the FDA-approved and off-label indications for tirzepatide therapy.
• Describe the mechanism of action of tirzepatide.
• Identify the potential adverse effects of tirzepatide.
• Summarize the contraindications for tirzepatide therapy.

Related products:

Product Photos:

Certifications:

Company:

FAQ: